Skip to main content
NewslettersWatchlist

Sage Therapeutic Com(SAGE-Q)
NASDAQ

Today's Change
Delayed Last Update
Day Low8.68
Day High8.74
Open:8.74
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Sage Therapeutic Com

Select a category then submit the form to load news
Motley Fool
Sage (SAGE) Q2 Revenue Jumps 264%
Tipranks
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and ZimVie Inc (ZIMV)
GlobeNewswire
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Business Wire
Sage Therapeutics Announces Second Quarter 2025 Financial Results
GlobeNewswire
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
GlobeNewswire
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
Business Wire
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
GlobeNewswire
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
Tipranks
J.P. Morgan Remains a Hold on SAGE Therapeutics (SAGE)
Stock Target Advisor
Analyst Coverage Updates: June 23rd, 2025
Untitled Why AMD Stock Slumped Today: Dimming AI Euphoria Signals Concern design
GlobeNewswire
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
Tipranks
Analysts’ Top Healthcare Picks: Surgery Partners (SGRY), SAGE Therapeutics (SAGE)
Tipranks
Scotiabank Sticks to Its Buy Rating for SAGE Therapeutics (SAGE)
Tipranks
H.C. Wainwright Keeps Their Hold Rating on SAGE Therapeutics (SAGE)
Tipranks
Truist Financial Reaffirms Their Hold Rating on SAGE Therapeutics (SAGE)
Tipranks
TD Cowen Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)
Tipranks
Wedbush Keeps Their Hold Rating on SAGE Therapeutics (SAGE)
GlobeNewswire
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
Tipranks
Bank of America Securities Sticks to Their Sell Rating for SAGE Therapeutics (SAGE)
Tipranks
J.P. Morgan Keeps Their Hold Rating on SAGE Therapeutics (SAGE)
Tipranks
SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial
Tipranks
Wedbush Remains a Hold on SAGE Therapeutics (SAGE)
Tipranks
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and BridgeBio Pharma (BBIO)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (ATRC), SAGE Therapeutics (SAGE) and Repligen (RGEN)
Tipranks
Piper Sandler Sticks to Their Buy Rating for SAGE Therapeutics (SAGE)
Tipranks
Analysts Conflicted on These Healthcare Names: Universal Health (UHS), SAGE Therapeutics (SAGE) and Henry Schein (HSIC)
Tipranks
SAGE Therapeutics (SAGE) Gets a Hold from Mizuho Securities
Tipranks
Morgan Stanley Keeps Their Hold Rating on SAGE Therapeutics (SAGE)
GlobeNewswire
Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Playstudios, Inc. (NASDAQ: MYPS); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your...
The Globe and Mail
Market movers: Stocks seeing action on Tuesday - and why
The CN Tower stands in the distance of a Bay Street sign displayed in Toronto, Ontario, Canada, on Tuesday, Feb. 5, 2013. dollar declined from almost a two-week high against its U.S. peer as stocks and commodities including crude oil, the nation’s biggest export, fluctuated. Photographer: Reynard Li/Bloomberg
Barchart
Stocks Close Lower as Bond Yields Climb
Wall Street - shutterstock_253136563
Barchart
Stocks Slide on Higher Bond Yields
Wall Street - shutterstock_1321462397

Profile

SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2025.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2025 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.